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ABSTRACT
Background and Objectives: There are limited published data on the incidence and cost 
associated with cardiac implantable electrical device (CIED) infection for Asian patients. We 
analyzed the infection burden associated with the implantation of CIEDs in Korea.
Methods: In the Health Insurance Review & Assessment Service (HIRA) database during the 
period from January 1, 2014 to December 31, 2016, we identified 16,908 patients with CIED 
implantation. CIED infection was defined as either: 1) Infection-related diagnosis code by 
the Korean Standard Classification of Diseases after any CIED procedure; or 2) CIED removal 
along with systemic infection.
Results: The proportions of first implantation and replacement were 77.6% and 22.4%, 
respectively. During the follow-up period of 17.1±10.6 months, a total of 462 patients had 
CIED infection with incidence of 1.95 per 100 person-years with higher infection rate in 
replacement than first implantation (3.97 vs. 1.4 per 100 person-years, p<0.001). The average 
cost per person was US$ 16,584 (pacemaker, $13,736; implantable cardioverter defibrillator, 
$28,402; cardiac resynchronization therapy, $29,674). The risk factors of CIED infection were 
generator replacement (adjusted hazard ratio [aHR], 3.14; 95% confidence interval [CI], 
2.60–3.78), diabetes mellitus (aHR, 1.94; 95% CI, 1.58–2.38), and congestive heart failure 
(aHR, 1.86; 95% CI, 1.51–2.28).
Conclusions: The rate of CIED infection in Korea was 1.95 per 100 person-years with average 
cost of US$ 16,584. The most important risk factor was generator replacement. This result 
suggests that generator replacement should be performed cautiously to avoid CIED infection.
Keywords: Pacemaker; Implantable cardioverter-defibrillator; Infection; Cost; Risk factors
INTRODUCTION
Cardiac implantable electrical device (CIED) therapy reduces morbidity and mortality 
in appropriately selected patients,1)2) but this benefit is thought to be mitigated by 
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complications, including infection.3) Infection in a permanently implanted CIED is a serious 
complication. It may occur either as a surgical site infection occurring within 1 year after 
implantation,4) or as late-onset lead endocarditis. CIED implantation rates are on the rise 
worldwide,5) and the population of patients living with a CIED is growing. As a consequence, 
CIED infections are also increasing. Although it is well recognized that the rate of CIED 
infection is increasing faster than the rate of CIED implantation,6)7) there are limited 
published data on the risk-adjusted mortality and cost associated with CIED infection or the 
relationship of these outcomes to different CIED types, especially in Asian countries.
Several studies8-11) have identified risk factors for infection in permanent CIED systems. 
However, the results of these studies are somewhat contradictory, and the risk factors for 
such infections have not been studied in a large cohort. This study sought to define the CIED 
infection rate, risk factors and cost with infection.
METHODS
Data source
In the Korea, almost the entire population has health insurance through National Health 
Insurance (NHI) or Medical Aid. Hospitals and clinics submit inpatient and outpatient 
claims data on spent cost covered by NHI or Medical Aid programs for reimbursement to 
the Health Insurance Review & Assessment Service (HIRA), which assesses the quality of 
the medical practice. HIRA collects patient clinical data through insurance claims, and the 
HIRA database is mainly open to researchers with academic or public policy purposes.12) 
The following information is provided: patients' gender and age information, their use of 
inpatient and outpatient services, pharmacy dispensing claims, medical device usage, and 
mortality data. This study was approved by the Institutional Review Board of Korea National 
Institute for Bioethics Policy (P01-201708-21-011), and informed consent was waived.
Study population
From the entire Korean population in the Korean HIRA database, 16,963 patients with 
newly-implanted CIED who were aged 19 years or older were identified during the period 
from January 1, 2014 to December 31, 2016. The study cohort was consisted of all admissions 
that included a procedure for CIED generator implantation, replacement, or revision 
identified using the corresponding NHI procedure codes for pacemakers (O0203, O0204, 
O0205, O0206, O0208, O0209 and O0210), implantable cardioverter defibrillators (ICDs) 
(O0211 and O0212), cardiac resynchronization therapy devices with defibrillator (CRT-D) 
(O0211 and O0212), or cardiac resynchronization therapy devices without defibrillator 
(CRT-P) (O0203,O0204, O0205 and O0206). The following were exclusion criteria: 1) 
those who were hospitalized less than 1 day (n=36), 2) those who had undergone epicardial 
pacemaker implantation (n=19). Finally, we included 16,908 patients who performed 
new CIED implantation (Figure 1). We excluded patient with hospital stay less than 24 
hours to prevent the erroneous case from being included in the study because it is rare for 
patient with pacemaker implantation was discharged within a day. We excluded epicardial 
pacemaker because of different procedure and higher complication rate than percutaneous 
pacemaker implantation.
Infection was identified using the Korean Standard Classification of Disease (KCD), Seventh 
Revision diagnosis codes for infection due to a cardiac and vascular device (T80, T81, T82 
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and T87), bacteremia (A48 and A49), septicemia (A40 and A41), shock (R57), or fever (R50). 
Admissions that included only electrode implantation, replacement, or revision without 
evidence of infection were not considered as infection.3)13) The type of CIED was classified to 
pacemaker, ICD and CRT-D/P. The pacemaker and ICD were subclassified as single chamber 
and dual chamber.
The more detailed definitions of CIED related procedures, devices and infections are 
presented in Supplementary Table 1. ICD-10 codes used for defining the comorbidities are 
presented in Supplementary Table 2.
Outcomes
Our analysis had 3 primary outcomes: infection, admission length of hospital stay, and 
admission cost. Admission costs were calculated with the method used by the Korean NHI to 
calculate costs for establishing payment rates under the Fee-For-Services System.
Statistical analysis
Continuous variables were expressed as mean±standard deviation (SD) and categorical 
variables were reported as frequencies (percentages). The categorical variables were 
compared by Fisher's exact test or Pearson χ2 test, and continuous variables were compared 
by the Student's t-test. Crude incidence rates for CIED infections were calculated by 
dividing the number of incident cases of CIED infection by the number of person-years 
accumulated in the population with CIED implantation or replacement.14) The 95% 
confidence interval (CI) and p value for difference between two incidence rates were 
calculated using the Poisson approximation. Kaplan-Meier survival curves for CIED 
infection according to implantation condition were constructed and compared using 
a log-rank test. Patients were censored at the time of death, end of follow-up, or other 
termination of CIED treatment. In order to investigate the association between the 
clinical conditions and the CIED infection, we used Cox proportional hazards regression 
models. The factors considered in the models are age, sex, and clinical variables, including 
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16,963 patients with newly-implanted CIED
who were aged 19 years or older
in the National Health Insurance claims data
during the period from January 1, 2014
to December 31, 2016










• Hospitalization < 1 day (n=36)
• Epicardial pacemaker (n=19)
Figure 1. Study population. 
CIED = cardiac implantable electrical device; HIRA = Health Insurance Review & Assessment Service; NHI = National 
Health Insurance.
replacement (vs. first implantation), diabetes mellitus, hypertension, congestive heart 
failure, and single chamber (vs. dual chamber). These variables used to construct the 
model were based on the results of previous studies that reported independent risk factors 
for CIED infection.15)16) Results are presented as hazard ratios±95% CIs. For the multiple 
regression model, only the risk factors in the final model are presented. All the tests were 
two-tailed, and p<0.05 was considered significant. The regressions were estimated using 
with SAS version 9.3 (SAS Institute Inc, Cary, NC, USA).
RESULTS
The characteristics of patients
A total of 16,908 patients underwent one or more CIED implantations during the study 
period. The numbers of pacemaker, ICD and CRT implantation were 13,440 (79.5%), 2,712 
(16.0%) and 698 (4.1%), respectively. The proportions of first implantation and replacement 
were 77.6% (n=13,113) and 22.4% (n=3,795), respectively. One or more CIED replacements 
were carried out in 3,795 (22.4%) patients. Patient characteristics at the time of first CIED 
implantation or replacement are shown in Table 1.
During the study period, CIEDs were removed without replacement in 229 (1.4%) patients. 
Whereas, the remaining 16,679 (98.6%) patients were living with an implanted CIED at the 
end of the study period.
Infections
During the follow-up period of 17.1±10.6 months, a total of 462 patients had infection with 
the incidence of 1.95/100 person-years. Among 462 patients with CIED infection, 132 (28.6%) 
patients had undergone the implantation of new CIED after the removal of infected CIED. 
The comparison of baseline characteristics of non-infected and infected groups is presented 
in Table 2. Compared with non-infected group, infected group was older, included more 
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Table 1. The comparison of clinical characteristics of patients with first implantation and replacement of CIED
Clinical characteristics Total (n=16,908) First implantation (n=13,113) Replacement (n=3,795) p value
Age (years) 68.7±13.7 68.7±13.4 68.6±14.6 0.88
Male 7,974 (47.2) 6,367 (48.6) 1,607 (42.3) <0.001
Comorbidity
Hypertension 14,112 (83.5) 11,106 (84.7) 3,006 (79.2) <0.001
Diabetes 8,695 (51.4) 6,975 (53.2) 1,720 (45.3) <0.001
Heart failure 9,211 (54.5) 7,379 (56.3) 1,832 (48.3) <0.001
Myocardial infarction 1,792 (10.6) 1,508 (11.5) 284 (7.5) <0.001
CKD or ESRD 2,161 (12.8) 1,746 (13.4) 415 (10.9) <0.001
Pacemaker 13,440 (79.5) 10,313 (78.6) 3,127 (82.4) <0.001
Single chamber 2,416 (14.3) 1,638 (12.5) 778 (20.5) <0.001
Dual chamber 11,024 (65.2) 8,675 (66.2) 2,349 (61.9) <0.001
ICD 2,712 (16.0) 2,207 (16.8) 505 (13.3) <0.001
Single chamber 1,626 (9.6) 1,329 (10.1) 297 (7.8) <0.001
Dual chamber 1,086 (6.4) 878 (6.7) 208 (5.5) 0.16
CRT-P 55 (0.3) 29 (0.2) 26 (0.7) <0.001
CRT-D 643 (3.8) 526 (4.0) 117 (3.1) <0.001
Medication
Aspirin 7,906 (46.8) 6,631 (50.6) 1,275 (33.6) <0.001
Warfarin 3,061 (18.1) 2,413 (18.4) 648 (17.1) <0.001
Data are presented as mean±standard deviation for continuous variables. Numbers in parenthesis are percentage.
CIED = cardiac implantable electrical device; CKD = chronic kidney disease; CRT-D = cardiac resynchronization therapy devices with defibrillator; CRT-P = cardiac 
resynchronization therapy devices without defibrillator; ESRD = end-stage renal disease; ICD = implantable cardioverter defibrillator.
male, and had comorbidities and replacement more frequently. Single chamber pacemaker 
and ICD, and CRT-P were more frequently implanted, and aspirin or warfarin were more 
frequently prescribed in infected than non-infected groups.
Table 3 shows infection rate according to type of CIED and first implantation or replacement. 
After the first CIED implantation, 259 had infection with the incidence of 1.4/100 person-
years. Whereas after replacement, 203 had infection with the incidence of 3.97/1,000 person-
years. CIED infection rate was higher after the replacement than the first CIED implantation 
(p<0.001). The incidence of infection was 1.88, 2.26 and 2.26/100 person-years in pacemaker, 
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Table 2. The comparison of clinical characteristics of non-infected and infected patients with CIED
Clinical characteristics Non-infected group (n=16,446) Infected group (n=462) p value
Age (years) 68.6±13.7 70.4±13.3 0.007
Male 7,740 (47.1) 234 (50.6) 0.021
Comorbidity
Hypertension 13,694 (83.3) 418 (90.5) <0.001
Diabetes 8,374 (50.9) 321 (69.5) <0.001
Heart failure 8,881 (54.0) 330 (71.4) <0.001
Myocardial infarction 1,714 (10.4) 78 (16.9) <0.001
CKD or ESRD 2,007 (12.2) 154 (33.3) <0.001
Pacemaker 13,090 (79.6) 350 (77.3) <0.001
Single chamber 2,339 (14.2) 77 (17.0) <0.001
Dual chamber 10,751 (65.4) 273 (60.3) <0.001
ICD 2,629 (16.0) 83 (18.3) <0.001
Single chamber 1,578 (9.6) 48 (10.6) <0.001
Dual chamber 1,051 (6.4) 35 (7.7) <0.001
CRT-P 54 (0.3) 1 (0.2) <0.001
CRT-D 624 (3.8) 19 (4.2) <0.001
Medication
Aspirin 7,637 (46.4) 269 (58.2) <0.001
Warfarin 2,944 (17.9) 117 (25.3) <0.001
Data are presented as mean±standard deviation for continuous variables. Numbers in parenthesis are percentage.
CIED = cardiac implantable electrical device; CKD = chronic kidney disease; CRT-D = cardiac resynchronization 
therapy devices with defibrillator; CRT-P = cardiac resynchronization therapy devices without defibrillator;  
ESRD = end-stage renal disease; ICD = implantable cardioverter defibrillator.
Table 3. Infection rate according to first implantation or replacement, and type of CIED
Type of CIED Number of patients Person-years Number of events Per 100 person-years (95% CI) p value
Overall CIED
Total 16,908 23,686.08 462 1.95 (1.93–1.97)
First implantation 13,113 18,562.53 259 1.40 (1.38–1.41) <0.001
Replacement 3,795 5,123.56 203 3.97 (3.91–4.02)
Pacemaker
Total 13,440 18,636.08 350 1.88 (1.86–1.90)
Single chamber 2,416 3,377.04 77 2.28 (2.23–2.33) 0.081
Dual chamber 11,024 15,260.71 273 1.79 (1.77–1.81)
First implantation 10,313 14,597.22 199 1.36 (1.34–1.38) <0.001
Replacement 3,127 4,038.86 140 3.47 (3.41–3.52)
ICD
Total 2,712 3,673.76 83 2.26 (2.21–2.31)
Single chamber 1,626 2,197.59 48 2.18 (2.12–2.25) 0.714
Dual chamber 1,086 1,476.17 35 2.37 (2.29–2.45)
First implantation 2,207 3,117.19 47 1.51 (1.47–1.55) <0.001
Replacement 505 556.57 36 6.47 (6.26–6.68)
CRT-P & CRT-D 698 885.93 20 2.26 (2.16–2.36)
First implantation 555 752.99 11 1.46 (1.38–1.55) 0.021
Replacement 143 132.94 9 6.77 (6.34–7.22)
CI = confidence interval; CIED = cardiac implantable electrical device; CRT-D = cardiac resynchronization therapy devices with defibrillator; CRT-P = cardiac 
resynchronization therapy devices without defibrillator; ICD = implantable cardioverter defibrillator.
ICD and CRT-P/D, respectively. In both pacemaker and ICD, there was no difference in 
infection rate between single and dual chamber.
The time to CIED infection is illustrated by Kaplan-Meier plots in Figure 2. After first 
implantation, infection occurred continuously. However, after replacement, the rate of 
infection increased abruptly at first 50 days, and increased continuously after 50 days.
Risk factors associated with infection
Our simple regression analysis indicated that the risk of CIED infection was increased by 
replacement, diabetes mellitus, hypertension, congestive heart failure, single chamber and 
older age.
According to our multiple regression analysis, the risk of CIED infection was increased by 
replacement with adjusted hazard ratio (aHR) of 3.15 (95% CI, 2.60–3.78), diabetes with 
aHR of 1.94 (95% CI, 1.58–2.38), and congestive heart failure with aHR of 1.86 (95% CI, 
1.51–2.50) (Table 4).
Hospitalization duration and medical cost related to cardiac implantable 
electrical device infection
The average hospitalization was 14.1±9.3 and 17.2±12.4 days for CIED infection after 
first implantation and replacement, respectively. The duration of hospitalization was 
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First implantation 13,113 11,747 10,376 9,976 7,764 6,566 5,445
Replacement 3,795 3,280 2,903 2,517 2,128 1,760 1,444
Figure 2. Kaplan-Meier curve for CIED infection in patients with first implantation and generator change of CIED. 
CIED = cardiac implantable electrical device.
Table 4. The risk factors of CIED infection
Variables Simple regression Multiple regression
*
HR 95% CI p value aHR 95% CI p value
Replacement (vs. first implantation) 2.81 2.33–3.38 <0.001 3.03 2.49–3.68 <0.001
Diabetes mellitus 2.19 1.80–2.68 <0.001 1.92 1.54–2.37 <0.001
Hypertension 1.97 1.41–2.75 <0.001 - - 0.16
Heart failure 2.01 1.72–2.54 <0.001 1.89 1.53–2.34 <0.001
Single chamber (vs. dual) 1.26 1.02–1.56 0.03 - - 0.77
Age (per 10-year increase) 1.01 1.00–1.02 0.001 - - 0.11
Sex (men vs. women) 1.22 1.00–1.48 0.05
aHR = adjusted hazard ratio; CI = confidence interval; CIED = cardiac implantable electrical device; HR = hazard ratio.
*The factors considered in the models are age, sex, and clinical variables, including replacement (vs. first implantation), diabetes mellitus, hypertension, 
congestive heart failure, and single chamber (vs. dual chamber).
significantly longer for replacement than first implantation of CIED (p=0.002). There 
was no significant difference of duration of hospitalization for CIED infection among 
pacemaker, ICD and CRT-P/D.
The average cost per person related to CIED infection was US$17,105. The average cost 
of replacement was more expensive than that of first implantation ($17,591±13,688 vs. 
$15,795±9,544, p=0.009). Compared with that of pacemaker ($13,736±10,049), the average 
costs for ICD ($28,402±8,448) and CRT-P/D ($29,674±9,012) were more expensive in CIED 
infection (Table 5).
DISCUSSION
The present study represents the nationwide population-based study of CIED infections, 
associated risk factors and medical cost of infection after first CIED implantations and CIED 
replacements. This study also provides the device type–specific estimates of cost associated 
with CIED infection in the current era of CIED use in Korea. Second, the replacement of CIED 
were associated with a substantial incremental risk of CIED infection. Although the majority 
of infections occurred within the first year of follow-up, a large number of infections were 
found to occur during the late follow-up period, >1 year post-implantation. This very late 
onset of infection is consistent with the findings from other studies that consider extended 
follow-up periods9)10)17) and with the current understanding of slowly progressing, implant-
related infection.18)
The incidence of CIED infection in our population was 1.41 per 100 person-years after the 
first implantation. This is similar to the rate of other epidemiological studies that include 
long-term follow-up have calculated cumulative rates per patient or device and report 
infection rates of 2.210) and 1.6%,9) respectively. The effect of this difference is unclear; the 
rate of infection in ICD systems has been reported to be similar to the rates observed for 
pacemaker systems.9)10)
The infection rate after CIED replacement was almost 2.64 times higher than that of first 
CIED implantation. This increase is similar was previous study that the incidence of surgical 
site infection was 4.82/1,000 pacemaker-years after first pacemaker implantation and 
12.12/1,000 pacemaker-years after pacemaker replacement.16)
The substantially elevated risk of infection after CIED replacements and other repeated 
procedures observed in the present study has been reported previously.9-11)19) The increased 
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Table 5. Hospitalization duration and medical cost related to CIED infection
Type of CIED Hospitalization (days) Cost, overall ($) Cost, per person ($)
Overall CIED
Total 15.5±10.9 7,661,910 16,584±11,570
First implantation 14.1±9.3 4,090,865 15,795±9,544
Replacement 17.2±12.4 3,571,045 17,591±13,688
Pacemaker 15.1±11.4 4,807,730 13,736±10,049
ICD 15.9±9.5 2,357,354 28,402±8,448
CRT-P & CRT-D 15.3±7.4 593,469 29,674±9,012
CIED = cardiac implantable electrical device; CRT-D = cardiac resynchronization therapy devices with 
defibrillator; CRT-P = cardiac resynchronization therapy devices without defibrillator; ICD = implantable 
cardioverter defibrillator.
risk of infection after repeated procedures argues strongly that industry should improve CIED 
batteries and that physicians should increase device longevity by appropriately programming 
CIED parameters. Furthermore, the increased risk of infection after repeated procedures 
should be considered in the decision-making process when handling device recalls,20) which 
are a common reason for premature repeated procedures. In each patient, the benefits of 
replacing the hardware should be balanced with the increased risk of device infection.
At first glance, the higher risk of infection after repeated procedures (most often simple CIED 
replacements) is unexpected, as these procedures most often involve only a minor surgical 
revision and are short-lasting compared with first implantations. It is generally recognized, 
however, that revision surgery is an important risk factor for the infection of an implanted 
prosthesis or device.21) Our findings could likely be explained by the fact that CIED pockets 
can be colonized by bacteria, even in the absence of any initial clinical signs of infection.22) In 
combination with the limited immunological response of the fibrous and poorly vascularized 
CIED pocket that is opened during replacement or revision procedures,23) the rapid formation 
of a microbial biofilm24) by either latent or perioperative inoculation of pathogens may be 
favored, thereby allowing pocket infection.
Beside CIED replacement, we also found that diabetes and hypertension were important risk 
factors. Prior studies have suggested that male sex, younger age, diabetes, underlying heart 
disease, implantation during the earliest part of the study period, and absence of antibiotics 
were associated with an increased risk of CIED infection.10)11)15-17) This study did not evaluated 
other potentially important procedure-related factors including the size of the implanting 
center, the complexity of the procedure, and the number of leads.
There are few published data on the current cost of managing CIED infection. Moreover, these 
analyses do not reflect the current patient population receiving CIED therapy. In US Medicare 
patients, the standardized adjusted incremental and total admission costs with infection were 
$14,360 to $16,498 and $28,676 to $53,349, respectively, depending on CIED type.25)
Although it is important to reduce admission costs associated with CIED infection, 
preventing infections or reducing the severity of infections through early detection would 
have a significant impact on both mortality and cost associated with these infections.
The present study is a retrospective analysis, and thus bears the inherent limitations of such 
studies. First, infections identified using KCD codes for cardiac or vascular device infection, 
or cardinal manifestations of infection, in the setting of a CIED implantation, were presumed 
to be CIED infections. We took an approach similar to Voigt et al.6)26) that incorporates 
multiple distinct code-based criteria to increase the sensitivity of the search. Because the 
rate of lead extraction is relatively low in Korea, we could not identify CIED infection using 
lead extraction. Moreover, we could not distinguish between major and minor infections. 
Second, we were not able to distinguish whether removal of the pacemaker system was due 
to infection arising from a device pocket infection or from a bloodstream infection of the 
intravascular portion of the system. However, data suggest an overlap between these two 
events.27)28) Third, although heterogeneous baselines imply potential interactions between 
replacement and diabetes mellitus and/or heart failure, this possibility was not investigated. 
Fourth, in this study, data from 2014 to 2016 were extracted and utilized for drawing results. 
Hence, these results may not properly capture current rates of CIED implantation (and 
related infection rates) if CIED is growing perhaps fast. Finally, the recent methods of lead 
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extraction, such as lasers or mechanical sheaths were not available. Therefore, this study may 
underestimate the incremental admission cost with infection. Despite these limitations, we 
believe these data provide useful insights into mortality and cost associated with infection of 
CIED as they are being used in current practice.
In conclusion, the rate of CIED infection in Korea was 1.95 per 100 person-years with 
average cost of US$ 16,584. The most important risk factor was generator replacement. 
This result suggests that generator replacement should be performed cautiously to avoid 
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